Department of Anesthesiology and Critical Care, Soroka University Medical Center, Ben-Gurion of the Negev, Beer-Sheva 84105, Israel.
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.
Int J Mol Sci. 2022 May 21;23(10):5796. doi: 10.3390/ijms23105796.
Acute ischemic stroke is a critical condition that can result in disability and death. The consequences of this medical condition depend on various factors, including the size of the stroke, affected brain region, treatment onset, and the type of treatment. The primary objective of stroke treatment is to restart ischemic penumbra tissue perfusion and reduce infarct volume by sustaining blood flow. Recent research on the condition's pathological pathways and processes has significantly improved treatment options beyond restoring perfusion. Many studies have concentrated on limiting injury severity via the manipulation of molecular mechanisms of ischemia, particularly in animal research. This article reviews completed and ongoing research on the development of acute ischemic stroke drugs. This study focuses on three main categories of antithrombotic drugs, thrombolytic drugs, and neuroprotective agents. The paper outlines findings from animal and clinical trials and explores the working mechanisms of these drugs.
急性缺血性脑卒中是一种严重的疾病，可能导致残疾和死亡。这种疾病的后果取决于多种因素，包括中风的大小、受影响的大脑区域、治疗开始时间以及治疗类型。中风治疗的主要目的是通过维持血流来重新启动缺血半影组织灌注并减少梗死体积。最近对该疾病病理途径和过程的研究除了恢复灌注之外，还显著改善了治疗选择。许多研究都集中在通过操纵缺血的分子机制来限制损伤的严重程度，特别是在动物研究中。本文综述了急性缺血性脑卒中药物开发的已完成和正在进行的研究。本研究主要关注抗血栓药物、溶栓药物和神经保护剂这三类药物。本文概述了动物和临床试验的结果，并探讨了这些药物的作用机制。
